{"id":"W3113132520","doi":"10.1016/j.annonc.2020.12.004","title":"Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Internal medicine; Oncology; Cancer; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001210987,0.001346125,0.001910172,0.0002474038,0.0002645207,0.001131061,0.0006032211,0.0007582591,0.00356519],"category_scores_gemma":[0.0007464828,0.0004362629,0.001812411,0.0002950398,0.0005133678,0.0009252107,0.0002792178,0.002944102,0.001010603],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008761283,"about_ca_system_score_gemma":0.0008367347,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009009779,"about_ca_topic_score_gemma":0.003334258,"domain_scores_codex":[0.9997228,0.0001136953,0.00001079627,0.00004638057,0.0000263118,0.00007997536],"domain_scores_gemma":[0.9996786,0.00006985811,0.00007151639,0.00002842862,0.00002476691,0.00012679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8560134,0.007704627,0.003455238,0.001531644,0.003602487,0.0001142476,0.00009089439,0.00241271,0.01209181,0.0005499103,0.00830747,0.1041255],"study_design_scores_gemma":[0.856226,0.1152211,0.01492811,0.000144866,0.003088064,0.0002888363,0.0001056685,0.002038967,0.00200488,0.0007498005,0.005150789,0.00005293691],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807488,0.009430953,0.0006919258,0.00113519,0.0004544089,0.0008230783,0.001919965,0.0001482675,0.004647416],"genre_scores_gemma":[0.9834396,0.005114849,0.001026345,0.001511474,0.0003550311,0.0008688127,0.003418177,0.00005669153,0.004209106],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00356519,"threshold_uncertainty_score":0.01192677,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06816358705992281,"score_gpt":0.3451095596220558,"score_spread":0.276945972562133,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}